Table 1. Efficacy and risk profile of DOACs versus VKAs.

Direct oral anticoagulant (DOAC)	RCTs comparing DOAC to warfarin for DVT	Difference in efficacy	Increased risk (DOAC vs. VKA)	Decreased risk (DOAC vs. VKA)
Dabigatran	RE-COVER, RE-COVER-II, RE-LY, REMEDY, RESONATE	–	GI bleeding, MI, ACS*	–
Rivaroxaban	EINSTEIN DVT	–	GI bleeding**	–
Apixaban	AMPLIFY	–	–	Major bleeding, non-major bleeding
Edoxaban	HOKUSAI-VTE	–	–	Non-major bleeding

*, RE-LY trial studied patients with atrial fibrillation; **, increased risk of ACS and MI demonstrated in several additional studies when used for reasons other than DVT. VKA, vitamin K-antagonist; MI, myocardial infarction; ACS, acute coronary syndrome; GI, gastrointestinal; RCTs, randomized controlled trials; DVT, deep vein thrombosis.